What do systematic reviews say?

Alkylating agents vs cyclosporin

It is very uncertain whether alkylating agents changes adverse effects: leucopenia compared with cyclosporin (very low certainty).

• Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
  RR 29.84 [1.84, 483.93]
  1 study · 66 participants
  Very low

Tacrolimus vs cyclosporin

Tacrolimus showed no clear difference in treatment response at 6 months: complete remission compared with cyclosporin (low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 1.14 [0.64, 2.03]
  1 study · 41 participants
  Low

Tacrolimus vs cyclosporin

Tacrolimus showed no clear difference in treatment response at 6 months: complete and partial remission compared with cyclosporin (low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 0.57 [0.16, 2.08]
  1 study · 41 participants
  Low
• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 1.05 [0.87, 1.25]
  2 studies · 58 participants
  Low

Tacrolimus vs cyclosporin

Tacrolimus showed no clear difference in treatment response at 12 months: complete remission compared with cyclosporin (low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 0.8 [0.45, 1.42]
  2 studies · 58 participants
  Low

Tacrolimus vs cyclosporin

Tacrolimus showed no clear difference in adverse events: persistent nephrotoxicity compared with cyclosporin (low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 0.48 [0.05, 4.85]
  1 study · 41 participants
  Low

Tacrolimus vs cyclosporin

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 58 participants
  Low

Summary of findings: punctal plugs vs cyclosporine A

• Punctal occlusion for dry eye syndrome 2017 · Cochrane Headline outcomes only
  no estimate extracted
  2 participants
  GRADE not reported

Summary of findings: punctal plugs vs cyclosporine A

• Punctal occlusion for dry eye syndrome 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 20 participants
  Very low

Summary of findings: punctal plugs vs cyclosporine A

• Punctal occlusion for dry eye syndrome 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 22 participants
  Very low

Summary of findings: punctal plugs vs cyclosporine A

• Punctal occlusion for dry eye syndrome 2017 · Cochrane Headline outcomes only
  no estimate extracted
  2 participants
  GRADE not reported

Summary of findings: punctal plugs vs cyclosporine A

• Punctal occlusion for dry eye syndrome 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 20 participants
  Very low

Summary of findings: punctal plugs vs cyclosporine A

• Punctal occlusion for dry eye syndrome 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 20 participants
  Very low

Azathioprine vs cyclosporin of remission

It is very uncertain whether azathioprine (AZA) changes failure to maintain remission compared with cyclosporin of remission (very low certainty).

• Azathioprine and 6‐mercaptopurine for maintenance of remission in ulcerative colitis 2016 · Cochrane Headline outcomes only
  RR 0.8 [0.33, 1.92]
  1 study · 16 participants
  Very low